0001415889-25-019390.txt : 20250703 0001415889-25-019390.hdr.sgml : 20250703 20250703210506 ACCESSION NUMBER: 0001415889-25-019390 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250701 FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moshkevich Solomon CENTRAL INDEX KEY: 0002010019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 251106837 MAIL ADDRESS: STREET 1: C/O NATERA, INC. STREET 2: 13011 MCCALLEN PASS, BLDG A, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 4 1 form4-07032025_090703.xml X0508 4 2025-07-01 0001604821 Natera, Inc. NTRA 0002010019 Moshkevich Solomon C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false PRESIDENT, CLINICALDIAGNOSTICS 1 Common Stock 2025-07-01 4 S 0 400 163.8764 D 132805 D Common Stock 2025-07-01 4 S 0 200 165.9850 D 132605 D Common Stock 2025-07-01 4 S 0 2109 167.2501 D 130496 D Common Stock 2025-07-01 4 S 0 291 167.79 D 130205 D The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.55 to $164.08 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.62 to $166.35 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.64 to $167.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Vincent Fontanilla, Attorney-in-Fact 2025-07-03